These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 12894380)

  • 21. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overlapping and distinct mechanisms of action of multiple sclerosis therapies.
    Graber JJ; McGraw CA; Kimbrough D; Dhib-Jalbut S
    Clin Neurol Neurosurg; 2010 Sep; 112(7):583-91. PubMed ID: 20627553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rationale for the use of mitoxantrone in multiple sclerosis.
    Edan G; Morrissey S; Le Page E
    J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
    Racke MK; Lovett-Racke AE; Karandikar NJ
    Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone and cytotoxic drugs' mechanisms of action.
    Vollmer T; Stewart T; Baxter N
    Neurology; 2010 Jan; 74 Suppl 1():S41-6. PubMed ID: 20038762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy of multiple sclerosis.
    Weiner HL; Hafler DA
    Ann Neurol; 1988 Mar; 23(3):211-22. PubMed ID: 3288084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific treatment of multiple sclerosis.
    Silberberg DH
    Clin Neurosci; 1994; 2(3-4):271-4. PubMed ID: 7749898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A practical approach to immunomodulatory therapy for multiple sclerosis.
    Burks JS
    Phys Med Rehabil Clin N Am; 2005 May; 16(2):449-66, ix. PubMed ID: 15893681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Recent progress in treatment for multiple sclerosis].
    Kira J
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1261-3. PubMed ID: 11464473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [MS Therapy Consensus Group. Immunomodulating staged therapy of multiple sclerosis].
    Nervenarzt; 1999 Apr; 70(4):371-86. PubMed ID: 10355003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myelin peptides in multiple sclerosis.
    Grau-López L; Raïch D; Ramo-Tello C; Naranjo-Gómez M; Dàvalos A; Pujol-Borrell R; Borràs FE; Martínez-Cáceres E
    Autoimmun Rev; 2009 Jul; 8(8):650-3. PubMed ID: 19393199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current trends in multiple sclerosis research: an update on pathogenic concepts.
    Vanderlocht J; Hellings N; Hendriks JJ; Stinissen P
    Acta Neurol Belg; 2006 Dec; 106(4):180-90. PubMed ID: 17323836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen-specific therapies in MS - Current concepts and novel approaches.
    Lutterotti A; Sospedra M; Martin R
    J Neurol Sci; 2008 Nov; 274(1-2):18-22. PubMed ID: 18599087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early treatment.
    Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S8-12. PubMed ID: 16708191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
    Kohm AP; Turley DM; Miller SD
    Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of immunomodulatory treatment of multiple sclerosis on lymphocyte surface immunomarkers.
    Michałowska-Wender G; Losy J; Wender M; Januszkiewicz-Lewandowska D; Nowak J
    Pol J Pharmacol; 2003; 55(5):877-80. PubMed ID: 14704481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
    Lopez-Diego RS; Weiner HL
    Nat Rev Drug Discov; 2008 Nov; 7(11):909-25. PubMed ID: 18974749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.